Emcure Pharmaceuticals: Difference between revisions
added multinational |
|||
| Line 2: | Line 2: | ||
| name = Emcure Pharmaceuticals Limited |
| name = Emcure Pharmaceuticals Limited |
||
| logo = EmcurePharmaceuticalsLogo.png |
| logo = EmcurePharmaceuticalsLogo.png |
||
| logo_alt = Logo of Emcure Pharmaceuticals Limited |
| logo_alt = Logo of Emcure Pharmaceuticals Limited |
||
| type = MNC (JVs and subsidiaries) |
| type = MNC (JVs and subsidiaries) |
||
| area_served = Worldwide |
|||
| key_people = Satish Mehta<ref>{{Cite web|url=https://www.bloomberg.com/markets/stocks|title=Stocks|website=Bloomberg.com}}</ref> [[Chief executive officer|CEO]], |
| key_people = Satish Mehta<ref>{{Cite web|url=https://www.bloomberg.com/markets/stocks|title=Stocks|website=Bloomberg.com}}</ref> [[Chief executive officer|CEO]], |
||
Namita Thapar<ref name="auto">{{Cite web|url=https://www.emcure.com/leadership|title=Board of Directors and Leadership Team | Emcure|website=www.emcure.com}}</ref> [[Executive Director]], |
Namita Thapar<ref name="auto">{{Cite web|url=https://www.emcure.com/leadership|title=Board of Directors and Leadership Team | Emcure|website=www.emcure.com}}</ref> [[Executive Director]], |
||
| Line 23: | Line 24: | ||
}} |
}} |
||
'''Emcure Pharmaceuticals''' is an Indian [[Pharmaceutical industry|pharmaceutical]] company headquartered in [[Pune]], [[Maharashtra]]. Emcure's product portfolio includes [[Tablet (pharmacy)|tablets]], [[Capsule (pharmacy)|capsules]] (both [[softgel]] capsules and hard-gel capsules), and injectables. |
'''Emcure Pharmaceuticals''' is an Indian multinational [[Pharmaceutical industry|pharmaceutical]] company headquartered in [[Pune]], [[Maharashtra]]. Emcure's product portfolio includes [[Tablet (pharmacy)|tablets]], [[Capsule (pharmacy)|capsules]] (both [[softgel]] capsules and hard-gel capsules), and injectables. |
||
== Indian plants == |
== Indian plants == |
||
Revision as of 11:23, 23 August 2021
 | |
| Company type | MNC (JVs and subsidiaries) |
|---|---|
| Industry | Pharmaceutical |
| Founded | 1983 |
| Headquarters | Hinjwadi, Pune, India |
Area served | Worldwide |
Key people | Satish Mehta[1] CEO,
Namita Thapar[2] Executive Director, Vik Thapar[2] President - Corporate Dev & Strategy, Samit Mehta[2] President - R&D |
| Products | tablets, capsules, softgels, injectables, Lyophilized sterile parenterals, Onco products |
| US$220 million | |
Number of employees | 11000+ |
| Website | www.emcure.com |
Emcure Pharmaceuticals is an Indian multinational pharmaceutical company headquartered in Pune, Maharashtra. Emcure's product portfolio includes tablets, capsules (both softgel capsules and hard-gel capsules), and injectables.
Indian plants
- Solid Dosage facility at Hinjawadi - In 2006, Emcure received US FDA approval for its solid dosages facility at Hinjwadi, Pune. The plant manufactures solid oral formulations for the international regulated markets.
- Small volume parenteral facility at Hinjawadi - US FDA, UK MHRA approved. Has lyophilization and pfs capability
- Oncology injectable facility at Hinjawadi
- Solid Orals facilities at Jammu and Bhosari
- API facility at Kurkumbh- US FDA approved
- Biotech facility at Hinjawadi
- R&D center at Gandhinagar and plant at Sanand, Ahmedabad.- Sanand facility is US FDA approved
US plant
USA - The company has a manufacturing facility and R&D center in East Brunswick, New Jersey, USA.
Capital markets
Emcure is planning to raise money through an initial public offering for some time now[3] In 2014, Blackstone sold its stake in Emcure to Bain Capital[4]
Recalls
In 2010, Pfizer had to recall three batches of an anti-bacterial product from the US market due to presence of Bacillus anthracis, Penicillium chrysogenum & E. coli in some samples.[5] Teva recalled several batches of two products due to white tablets showing presence of Yersinia pestis in 2011.[6]
AIDS Initiative
Emcure voices its concerns on HIV/AIDS through its "Let's fight AIDS together" initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility it supports 'Taal', a pharmacy for HIV/AIDS patients run by HIV/AIDS patients.
Emcure has license agreements with Bristol-Myers Squibb for Atazanavir[7] and Gilead Sciences for Tenofovir[citation needed] as part of their Global Access Programs.
Anticancer portfolio
Roche has signed a deal with Emcure for manufacturing its blockbuster anticancer drugs Herceptin and Mabthera in India.[5] Under this programme the cancer drugs shall be made available to the developing world at an affordable 'cut-price' version.[8]
Price fixing
Heritage Pharmaceuticals, a division of Emcure has entered into a deferred prosecution agreement[9] with the United States Department of Justice, Antitrust Division ("DOJ") relating to a one-count Information for a conspiracy involving glyburide. In conjunction with the DPA, Heritage will pay a $225,000 fine. [10]
In addition, the Company separately agreed to a settlement with the United States Department of Justice, Civil Division to resolve potential civil liability under the False Claims Act in connection with the antitrust conduct. Under the terms of the settlement, the Company has agreed to pay $7.1 million. Heritage has agreed to pay $7.1 million as part of a settlement with DOJ's Civil Division to resolve allegations of selling drugs at the artificially inflated prices, which resulted in claims submitted to or purchases by federal healthcare programs
References
- ^ "Stocks". Bloomberg.com.
- ^ a b c "Board of Directors and Leadership Team | Emcure". www.emcure.com.
- ^ "Latest News: India News | Latest Business News | BSE | IPO News". Moneycontrol.
- ^ "Blackstone to sell Emcure Pharmaceuticals stake to Bain Capital - Indian Express". archive.indianexpress.com.
- ^ a b "Business News Today: Read Latest Business news, India Business News Live, Share Market & Economy News". The Economic Times.
- ^ "Archived copy". Archived from the original on 2011-05-20. Retrieved 2012-04-25.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ Bureau, Our Corporate (February 17, 2006). "Bristol-Myers outsources AIDS drug to Emcure" – via Business Standard.
{{cite web}}:|last=has generic name (help) - ^ "Archived copy". Archived from the original on 2012-08-01. Retrieved 2012-04-12.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ "Pharmaceutical Company Admits to Price Fixing in Violation of Antitrust Law, Resolves Related False Claims Act Violations". www.justice.gov. May 31, 2019.
- ^ "Pharmaceutical Company Official dealer to Price Fixing in Violation of Antitrust Law, Resolves Related False Claims Act Violations". mhp.ooo. May 22, 2010.
